Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-A12 (cixutumumab) +/- antiestrogens in advanced breast cancer
NCT00728949Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2008
- Primary completion
- Mar 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cixutumumab in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Progression-Free Survival at 35.1 months and Overall Survival at 36.5 months. Started Aug 2008; status: completed.
02
Drugs
cixutumumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00728949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00728949.